ACELRX PHARMACEUTICALS INC (ACRX) Stock Price, Forecast & Analysis
NASDAQ:ACRX • US00444T2096
ACRX Key Statistics, Chart & Performance
The current stock price of ACRX is 0.86 USD. In the past month the price increased by 18.03%. In the past year, price decreased by -66.8%.
ACRX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ACRX. When comparing the yearly performance of all stocks, ACRX is a bad performer in the overall market: 81.14% of all stocks are doing better.
ACRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ACRX. ACRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ACRX Financial Highlights
Over the last trailing twelve months ACRX reported a non-GAAP Earnings per Share(EPS) of -2.23. The EPS increased by 50.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -113.65% | ||
| ROE | -144.7% | ||
| Debt/Equity | 0 |
ACRX Forecast & Estimates
8 analysts have analysed ACRX and the average price target is 4.72 USD. This implies a price increase of 448.55% is expected in the next year compared to the current price of 0.86.
For the next year, analysts expect an EPS growth of 72.27% and a revenue growth -91.49% for ACRX
ACRX Ownership
ACRX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.65 | 985.228B | ||
| JNJ | JOHNSON & JOHNSON | 21.04 | 593.362B | ||
| MRK | MERCK & CO. INC. | 22.63 | 307.597B | ||
| PFE | PFIZER INC | 9.02 | 154.31B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.07 | 125.402B | ||
| ZTS | ZOETIS INC | 18.78 | 56.699B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.7 | 26.207B | ||
| VTRS | VIATRIS INC | 6.36 | 18.503B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.67 | 13.107B | ||
| AXSM | AXSOME THERAPEUTICS INC | 200.52 | 8.567B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ACRX
Company Profile
AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The company is headquartered in San Mateo, California and currently employs 19 full-time employees. The company went IPO on 2011-02-11. The firm is focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is its nafamostat formulation for direct intravenous (IV) infusion being explored as an investigational product for the antiviral treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. Its pre-filled syringe product candidates include Fedsyra and Phenylephrine.
Company Info
ACELRX PHARMACEUTICALS INC
1850 Gateway Drive, Suite 175
San Mateo CALIFORNIA 94063 US
CEO: Vincent J. Angotti
Employees: 19
Phone: 16502163500
ACELRX PHARMACEUTICALS INC / ACRX FAQ
What does ACRX do?
AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The company is headquartered in San Mateo, California and currently employs 19 full-time employees. The company went IPO on 2011-02-11. The firm is focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is its nafamostat formulation for direct intravenous (IV) infusion being explored as an investigational product for the antiviral treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. Its pre-filled syringe product candidates include Fedsyra and Phenylephrine.
Can you provide the latest stock price for ACELRX PHARMACEUTICALS INC?
The current stock price of ACRX is 0.86 USD. The price increased by 7.5% in the last trading session.
Does ACELRX PHARMACEUTICALS INC pay dividends?
ACRX does not pay a dividend.
How is the ChartMill rating for ACELRX PHARMACEUTICALS INC?
ACRX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the expected growth for ACRX stock?
The Revenue of ACELRX PHARMACEUTICALS INC (ACRX) is expected to decline by -91.49% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for ACELRX PHARMACEUTICALS INC?
ACELRX PHARMACEUTICALS INC (ACRX) has a market capitalization of 14.58M USD. This makes ACRX a Nano Cap stock.